The BELIEVE-VHL Trial is a prospective real-life study designed to evaluate the therapeutic effects, benefits, and adverse effects of belzutifan, as well as the timing of treatment response and disease progression in patients with von Hippel-Lindau (VHL) syndrome.
Age ≥ 14 years.
Clinical or genetic confirmation of von Hippel-Lindau (VHL) syndrome.
Presence of measurable or progressive VHL-associated tumors, as defined by RECIST 1.1 or disease-specific imaging criteria.
ECOG performance status of 0-2.
Age < 14 years.
Absence of a confirmed diagnosis of von Hippel-Lindau (VHL) syndrome.
Presence of an active malignancy outside the VHL tumor spectrum within the past 3 years, except for adequately treated basal or squamous cell carcinoma of the skin, cervical carcinoma in situ, or other malignancies considered cured for >2 years.
Known hypersensitivity or allergic reaction to belzutifan or any excipient in the formulation.
José Claudio Casali da Rocha
Lead sponsor
AC Camargo Cancer Center
Sponsor institution
AC Camargo Cancer Center
Collaborator